Intrommune Therapeutics

Early Stage

Intrommune Therapeutics is a New York City-based biopharmaceutical company developing a new, simple treatment for food allergies.

Analytics

Raised to Date: Raised: $157,806

Aggregate Commitments $

Platform

Netcapital

Start Date

04/13/2018

Close Date

06/29/2018

Min. Goal

$10,000

Max. Goal

$1,069,950

Min. Investment

$99

Security Type

Equity - Common

Funding Type

RegCF / RegD 506(c)

Price Per Share

$1.00

Pre-Money Valuation

$15,000,000

Rolling Commitments $

Status
Funded
Reporting Date

07/08/2018

Days Remaining
Funded
% of Min. Goal

1,578%

% of Max. Goal

15%

Likelihood of Max
Funded
Avg. Daily Raise

$2,049

Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Location

New York, New York

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

What if treating your allergies was as easy as….brushing your teeth? Well, with Intrommune Therapeutics, it now just might be! This New York City-based biopharmaceutical company is developing a toothpaste that uses oral mucosal immunotherapy (OMIT) to help people with peanut allergies overcome them. OMIT is based on allergy immunotherapy, which adheres to the idea that if patients receive tiny, carefully controlled amounts of the substance they are allergic to, their immune system learns that the substance is safe, and their allergic reactions become milder. Intrommune’s great-tasting, cavity-fighting toothpaste exposes patients to a low, safe dose of a peanut-derived protein in the toothpaste, with the goal of desensitizing the immune system’s reaction. They are developing this toothpaste in accordance to FDA guidelines, and there is no current FDA-approved treatment for any peanut for food allergy.
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Intrommune Therapeutics 07/07/2021 Self Managed - $0 Equity - Common Funded RegD 506(c)
Intrommune Therapeutics 06/29/2018 Netcapital $15,000,000 $157,806 Equity - Common Funded RegCF / RegD 506(c)
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$12.42 /month
billed annually
Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings (excluding risk)
Advanced company search ( with ratings)
Markets page filters and historical industry data
Get Edge Annual

Edge Pro

$41.58 /month
billed annually
Full site access including KingsCrowd's qualitative analyst reports.
Plan Includes:
Everything in Edge, plus
Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
Search and filter based on Analyst Reports
In-depth risk ratings for every raise
Get Edge Pro Annual
Already a member? Log in here.

Create your first portfolio

Create your very own investment portfolio on KingsCrowd.

Now you can track all of your startup investments in one place utilizing our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
Intrommune Therapeutics on Netcapital
$
Platform: Netcapital
Security Type: Equity - Common
Valuation: $15,000,000
Invest in a different round for this company? Use my investment date to determine which raise I invested in.

Follow company

Follow Intrommune Therapeutics on Netcapital
View on Netcapital (Closed)
Bullish / Bearish
You're Bullish on Intrommune Therapeutics on Netcapital

Thank you for your vote on Intrommune Therapeutics on Netcapital

Bullish / Bearish
You're Bearish on Intrommune Therapeutics on Netcapital

Thank you for your vote on Intrommune Therapeutics on Netcapital